Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 10/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 9/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 8/20 | 1.00 |
| ▸ | AKT1 | P31749 | 6/20 | 1.00 |
| ▸ | MTOR | P42345 | 13/20 | 0.67 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.63 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.63 |
| ▸ | PRKDC | P78527 | 2/20 | 0.63 |
| ▸ | ATM | Q13315 | 2/20 | 0.63 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | CSF1R | P07333 | 1/20 | 0.63 |
| ▸ | MET | P08581 | 1/20 | 0.63 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.63 |
| ▸ | LTK | P29376 | 1/20 | 0.63 |
| ▸ | CDK7 | P50613 | 1/20 | 0.63 |
| ▸ | NEK2 | P51955 | 1/20 | 0.63 |
| ▸ | JAK3 | P52333 | 1/20 | 0.63 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29703086 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CGPIK3CBAKT1 | |
| SCHEMBL930563 | 0.86 | PIK3CA (0.76) | PIK3CAPIK3CDPIK3CGPIK3CBAKT1 | |
| SCHEMBL5614520 | 0.86 | PIK3CA (0.75) | PIK3CAPIK3CDPIK3CGPIK3CBAKT1 | |
| SCHEMBL5615219 | 0.84 | PIK3CD (0.73) | PIK3CAPIK3CDPIK3CGPIK3CBAKT1 | |
| SCHEMBL5614860 | 0.84 | PIK3CA (0.73) | PIK3CAPIK3CDPIK3CGPIK3CBAKT1 | |
| SCHEMBL5614652 | 0.84 | PIK3CA (0.73) | PIK3CAPIK3CDPIK3CGPIK3CBAKT1 | |
| SCHEMBL5614853 | 0.84 | AKT1 (0.73) | PIK3CAPIK3CDPIK3CGPIK3CBAKT1 | |
| SCHEMBL5653651 | 0.83 | PIK3CA (0.72) | PIK3CAPIK3CDPIK3CGPIK3CBAKT1 | |
| SCHEMBL15747853 | 0.83 | MTOR (0.72) | PIK3CAPIK3CDPIK3CGPIK3CBAKT1 | |
| SCHEMBL15747737 | 0.83 | MTOR (0.72) | PIK3CAPIK3CDPIK3CGPIK3CBAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013029116-A1 | METHOD FOR PREDICTING TREATMENT RESPONSIVENESS | MONASH UNIVERSITY (AU) | 2013-03-07 | — | — | WO | claimed |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | CAPRARO HANS-GEORG | 2007-09-13 | — | — | US | claimed |
| JP-2007511576-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1689747-A1 | 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | claimed |
| WO-2005054238-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | claimed |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | disclosed |
| US-20180177776-A1 | COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (US) | 2018-06-28 | — | — | US | disclosed |
| WO-2016209688-A1 | COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2013082660-A1 | PREDICTION METHOD | ALFRED HEALTH (AU) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013029116-A1 | METHOD FOR PREDICTING TREATMENT RESPONSIVENESS | MONASH UNIVERSITY (AU) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | PIK3CA, MTOR, PIK3CD | PIK3CA 1/4885PIK3CD 3/4885PIK3CG 5/4885 |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | ABL1, PRKCA, PRKCQ | PIK3CA 466/4885PIK3CD 304/4885PIK3CG 366/4885 |
| US-20180177776-A1 | COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF | PIK3CA, MTOR, PIK3CD | PIK3CA 1/4885PIK3CD 3/4885PIK3CG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.